About Etanercept
Etanercept is a tumor necrosis factor antagonist that is used for the treatment of adult and juvenile from rheumatoid arthritis, it is also known as biopharmaceutical which is also used to treat autoimmune disorders. This biopharmaceutical is the United States FDA approved to treat psoriatic arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis and many more diseases. Hence, rising accidents and obesity is growing in the industry.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Etanercept market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Amgen (United States), Pfizer (United States), Takeda (Japan), Sanofi (France), GlaxoSmithKline (United Kingdom), Sandoz (Germany), Celltrion (South Korea), Dexa Medica (Indonesia), Bionovis (Brazil) and Momenta Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are HanAll Biopharma (South Korea), MedImmune (United States) and Tsumura (Japan).
Segmentation Overview
AMA Research has segmented the market of Global Etanercept market by Type (Enbrel and Benepali), Application (Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis (JIA) and Others) and Region.
On the basis of geography, the market of Etanercept has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form Type, the sub-segment i.e. Injection Solution will boost the Etanercept market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage, the sub-segment i.e. 25mg/0.5mL (Enbrel, Erelzi, Eticovo) will boost the Etanercept market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers:
Increasing Prevalence of Rising Diseases such as Obesity and Accidents and Rising Awareness about the Diseases such as Arthritis is also Driving the Market
Challenges:
Issue Related Towards the Side Effects of this Etanercept such as Lower Ability of Immune System, Heart failure and Many More
Restraints:
Growing Government Regulation Associated with Saftey and Efficiency of Etanercept can Hamper the market
Opportunities:
Growing Healthcare Expenditure and Government Support is Boosting the Industry
Lupin Limited has launched of Nepexto®, biosimilar etanercept, in the German market. Nepexto® is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis from the age of 2 years, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents from the age of 6 years. Nepexto® is approved for all therapeutic indications of the reference product Enbrel®.
In the United States, Sandoz submitted a biologics license application (BLA) for the proposed etanercept product "GP2015" in July 2016. Upon acceptance of the first application process, the U.S. FDA reviewed data from European clinical trials and bio-analytical investigations, demonstrating the biosimilarity of GP2015 to the US-licensed Enbrel
Key Target Audience
Etanercept Manufacture, Etanercept Distributors, Potential Investors, Pharmaceuticals and Others
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.